Clinical studies evaluating two novel incretin-based therapiesdipeptidyl-peptidase-4 (DPP-4) inhibitors and the incretin mimetic exenatide -have been reported. DPP-4 inhibitor and exenatide therapy effectively lower glycated haemoglobin (HbA 1c ) levels in patients with diabetes. Although HbA 1c reductions are similar with both incretinbased treatments, the results of clinical studies need to be put into perspective considering that the cited studies have different study populations and study designs. For example, exenatide has been shown to reduce HbA 1c levels in patients with a longer duration of type 2 diabetes (4.9-9.9 years). In addition, exenatide is associated with a mean reduction in body weight (1.3-2.8kg), whereas DPP-4 inhibitors are not associated with weight loss. Head-to-head comparisons between DPP-4 inhibitors and exenatide are lacking. In this manuscript, clinical studies published to date for the DPP-4 inhibitors sitagliptin and vildagliptin and for exenatide were evaluated with respect to study population, study design and effectiveness.
Introduction
Diabetes is associated with long-term microvascular and macrovascular complications and is widely recognised as one of the leading causes of mortality and morbidity. Population growth, ageing, urbanisation, the prevalence of obesity and a sedentary lifestyle are all factors associated with the dramatically growing type 2 diabetes epidemic. 1 Progressive beta-cell dysfunction and insulin resistance are the two core defects in the complex disease process of type 2 diabetes. When beta-cells fail to increase insulin secretion to compensate for the rising need of insulin to maintain euglycaemia in the setting of insulin resistance, type 2 diabetes occurs. However, besides insulin, glucagon is an important regulator of glucose metabolism and is responsible for the stimulation of glucose production by the liver. In type 2 diabetes, plasma glucagon concentrations are often elevated, leading to an increase in hepatic glucose output. Insulin and glucagon secretion are influenced by the incretin hormone glucagon-like peptide-1 (GLP-1), which is secreted by the L-cells of the intestinal mucosa after a meal. GLP-1 stimulates insulin secretion after a meal and suppresses glucagon secretion. In this way, GLP-1 helps to maintain normoglycaemia. In type 2 diabetes, exogenous GLP-1 can normalise blood glucose. 2 Two innovative therapeutic options based on the incretin concept are now available for the management of type 2 diabetes mellitus: the first, incretin mimetic (exenatide) and the second, DPP-4 inhibitors (sitagliptin and vildagliptin). While sitagliptin has already been authorised for marketing, vildagliptin is still under review. [3] [4] [5] [6] The basis for these therapeutic modalities is the utilisation of the physiological properties of the incretin hormones, in particular GLP-1. GLP-1 not only stimulates insulin secretion under hyperglycaemic conditions and inhibits glucagon secretion, but also slows gastric emptying and acts as a mediator of satiety in the central nervous system. In animal studies and in vitro, it increases the beta-cell mass and improves beta-cell function. 4 As GLP-1 itself is not feasible for therapeutic purposes because of its short biological half-life, two approaches were developed as a means of utilising the favourable effects of GLP-1 in treating type 2 diabetes through the use of elevated concentrations of GLP-1 receptor ligands.
One approach is to use long-acting incretin mimetics for subcutaneous administration. Exenatide is the first incretin mimetic to be authorised, and others are under development. The second therapeutic option is inhibition of incretin degradation by blockade of the DPP-4 enzyme.
Unlike subcutaneously administered incretin mimetics, DPP-4 inhibitors are effective when taken orally. 4, 5 DPP-4, also known as CD26, is an ubiquitous enzyme that degrades GLP-1 and gastric inhibitory polypeptide (GIP) as well as numerous other peptide hormones with the amino acid alanine or proline in position 2 of the N-terminus. 7 In Europe, sitagliptin was authorised in March 2007 as a combination therapy with either metformin or a thiazolidinedione. A second DPP-4 inhibitor (vildagliptin) has been submitted for approval. 9 Exenatide is the synthetic version of exendin-4, a naturally occurring 39 amino acid peptide, which exhibits 50% sequence identity to GLP-1. The aim of this paper is therefore to assess the existing clinical phase III trials on exenatide, sitagliptin and vildagliptin in terms of their study population and study design, efficacy (measured on the basis markers of glycaemia and body weight developments) and safety markers such as hypoglycaemia and adverse events.
Methods
Fourteen phase III clinical trials on the drugs exenatide, sitagliptin and vildagliptin were evaluated in terms of study population, study design, effectiveness (based on glycaemic control and weight) and safety. The differences between the patient cohorts investigated in the studies were analysed and compared in respect to disease duration and previous antidiabetic medication, in order to possibly identify those patients most likely experiencing benefit from these new treatment options. 
Exenatide
Exenatide shares similar glucoregulatory activities with the incretin hormone GLP-1, having multiple mechanisms of action that improve glycaemic control. 10 Exenatide, which is primarily metabolised in the kidney, exhibits a half-life of approximately 2.5 hours and can be found in the circulation six to 10 hours after a single dose. 10 Recently, intravenous infusion of exenatide has been shown to restore first-and second-phase insulin secretion after glucose challenge in patients with type 2 diabetes. 11 These results suggest that short-term intravenous administration of exenatide can acutely improve pancreatic beta-cell function in patients with type 2 diabetes.
The efficacy of glycaemic control with exenatide in patients with type 2 diabetes treated with metformin, a sulphonylurea or both has been investigated in three triple-blind, placebo-controlled, phase III clinical trials. [12] [13] [14] reduction achieved from baseline was -0.77% to -0.86%, respectively, compared with a 0.1-0.2% increase in placebo groups. [12] [13] [14] Furthermore, there were progressive reductions in mean bodyweight in subjects treated with 10µg exenatide and concomitant therapy: with sulphonylurea, 1.3kg; with sulphonylurea and metformin, 1.6kg; and with metformin, 2.8kg. [12] [13] [14] Exenatide was generally well tolerated and there were no severe adverse drug effects, other than one case of severe hypoglycaemia in combination with metformin and sulphonylurea. The most common adverse effect was nausea (45-51%). The incidence of nausea was the greatest when the exenatide dose was titrated from 5 to 10µg during the initiation phases of the trials, from weeks four to eight in the 30-week placebocontrolled trials. Incidence of nausea declined in patients with continuous exposure to exenatide. In all the trials, episodes of increase in the incidence of hypoglycaemia was observed in the combination therapy of exenatide and metformin. However, the incidence of hypoglycaemia in exenatide-treated patients increased when sulphonylurea was co-administered. In one of the three placebocontrolled phase III trials, it was observed that reducing the sulphonylurea dose decreased the incidence of hypoglycaemia in exenatide-treated patients. 14 In addition, the same trial showed that a baseline HbA 1c level close to 7% was associated with a higher incidence of hypoglycaemia. Low-titre antiexenatide antibodies and, in a few cases, high-titre antiexenatide antibodies were detected in some exenatide-treated patients; however, the presence of those antibodies had no predictive effect on glycaemic control or the incidence of adverse events. 15 In two other exenatide studies, patients taking a metforminsulphonylurea combination therapy were treated with two different types of insulin (glargine and biphasic insulin aspart) or exenatide. The duration of diabetes in the study patients was 9.8 and 9.9 years, respectively. These studies did not incorporate a washout period for the oral pre-treatment. 16, 17 According to the inclusion criteria, enrolment was limited to patients receiving an optimally tolerated dose of OAD agents.
Hence, this was a patient population that met European Association for the Study of Diabetes and American Diabetes Association criteria for initiation of insulin treatment. 18 In a 26-week open-label, randomised, controlled trial involving 551 patients with type 2 diabetes having inadequate glycaemic control despite the combination of metformin and sulphonylurea therapy, exenatide therapy provided glycaemic control that was non-inferior to insulin glargine. 16 In this study, HbA 1c reduction of -1.1% was achieved both on insulin glargine and on exenatide, starting with a baseline HbA 1c of 8.2% and 8.3%, respectively. 16 Patients receiving 10µg exenatide twice daily experienced progressive weight loss and had a mean reduction in bodyweight of 2.3kg. In contrast, patients receiving insulin glargine gained weight during the trial and had a mean weight gain of 1.8kg. Nausea (57.1%) and vomiting (17.4%) were the most frequent adverse events in exenatidetreated patients. Patients receiving exenatide had a significantly higher incidence of gastrointestinal adverse effects -including nausea, vomiting and diarrhoea -than patients receiving insulin glargine. The two treatment groups had no difference in the overall rate of hypoglycaemia (7.3 events/patient-year in the exenatide group versus 6.3 events/patient-year in the insulin glargine group), but patients receiving exenatide had a lower incidence of nocturnal hypoglycaemia and a higher incidence of daytime hypoglycaemia than patients receiving insulin glargine. 16 The safety and efficacy of exenatide versus biphasic insulin aspart was studied in a 52-week, randomised, open-label, non-inferiority trial in patients with type 2 diabetes taking metformin and a sulphonylurea who could not achieve optimal glycaemic control. An HbA 1c reduction of 0.89 and 1.04%, respectively, was observed in patients with the same baseline versus biphasic insulin aspart, 1.1±0.2 events/patient-year) were similar between treatment groups. Furthermore, this trial observed that reduction in sulphonylurea dose decreased the overall hypoglycaemia rates in exenatide-treated patients. 17 Weight reductions of 2.3 and 2.5kg with exenatide were observed in the In one of the three placebo-controlled phase III trials, it was observed that reducing the sulphonylurea dose decreased the incidence of hypoglycaemia in exenatide-treated patients.
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glargine and aspart studies comparing exenatide with insulins. In contrast, insulin glargine was associated with a weight gain of 1.8kg and insulin aspart with a weight gain of 2.9kg. 16, 17 Overall, it appears in clinical trials with exenatide that patients had a longer duration of diabetes (see Table 1 In a placebo-controlled vildagliptin study, drug-naïve patients were treated with the study drug for 24 weeks, preceded by a two-to fourweek run-in period. HbA 1c levels decreased by 0.80% from baseline HbA 1c levels of 8.3%. Vildagliptin did not have an effect on bodyweight. No confirmed hypoglycaemia was reported and adverse events occurred with similar frequency in each group. 23 In another placebo-controlled trial, vildagliptin was added to pre-existing metformin therapy. Treatment duration with study drug was 24 weeks, preceded by a two-to four-week run-in period. After 24 weeks of treatment, HbA 1c levels decreased by 0.90% from baseline HbA 1c levels of 8.4%. There was no effect on body weight. Only one mild hypoglycaemia occurred in each treatment group and vildagliptin was generally well tolerated. 22 In a study comparing vildagliptin with an active comparator, rosiglitazone drug-naïve patients had a mean duration of diabetes of 2.3 (vildagliptin) and 2.7 (rosiglitazone) years and baseline HbA 1c of 8.7% in both treatment groups. 24 After 24 weeks, a 1.3 and 1.1% reduction in HbA 1c was observed for rosiglitazone and vildagliptin, respectively. Vildagliptin met the statistical criterion for non-inferiority. Rosiglitazone had favourable effects in reducing fasting blood glucose. Vildagliptin did not result in weight gain, while the rosiglitazone patients gained weight.
In another study, vildagliptin (100mg) with pioglitazone (30mg) and a low-dose (50mg + 15mg) and high-dose (100mg + 30mg) vildagliptin-pioglitazone combination were compared. 25 In this fourarm 24-week study, patients had a short duration of diabetes Table 2 ). 25 In the clinical trials, vildagliptin was generally well tolerated, with no increased risk of hypoglycaemia compared with placebo.
Sitagliptin
Recently, sitagliptin (MK-0431, Merck, Whitehouse Station, New Jersey) has been authorised for the treatment of type 2 diabetes in Europe. In Europe, sitagliptin is authorised as combination therapy with either metformin or a thiazolidinedione. In the four evaluated placebocontrolled sitagliptin studies (100mg p.o. once daily), the mean diabetes duration in the study population was 4.4-6.2 years. [26] [27] [28] [29] With respect to prior antidiabetes treatment, subjects were drug-naïve or had received single-agent therapy with metformin or pioglitazone or dual low-dose combination therapy (metformin plus sulphonylurea, though only one subgroup in one study). In addition to the two-week placebo run-in periods, these studies also included washout periods (10-21 weeks) during which the prior treatments were not taken. Baseline HbA 1c in these studies was established after the washout period. One published study included an active sulphonylurea comparator, Table 3 ). In the clinical trials, sitagliptin was generally well tolerated, with no increased risk of hypoglycaemia compared with placebo.
Conclusion
Study participants in the exenatide studies were mainly patients with a longer diabetes duration (4.9 to 9.9 years). [12] [13] [14] 16, 17 In contrast, the DPP-4 inhibitor study patients [22] [23] [24] [25] [26] [27] [28] [29] [30] had shorter diabetes duration exenatide. 16, 17 In these studies, exenatide was non-inferior to insulin aspart and glargine in terms of HbA 1c reduction and led to reduced bodyweight, while insulin therapy was associated with significant weight gain. 16, 17 Another difference in the results of the cited exenatide and DPP-4 studies is that DPP-4 inhibitors were not associated with weight loss, [7] [8] [9] [22] [23] [24] [25] [26] [27] [28] [29] [30] while exenatide demonstrated the additional benefit of significant weight reduction. 6, [12] [13] [14] [16] [17] [18] Exenatide and DDP-4 inhibitors have a low potential to cause hypoglycaemia. The incidence of hypoglycaemia with exenatide is increased in combination with sulphonylureas due to this co-medication. In combination regimens of this kind, reduction of the sulphonylurea dose should be considered. 4 With respect to the side effects profile, exenatide is associated with an increase in nausea, most of which is mild to moderate (33-57% of patients reported at least one episode of nausea during the studies), and tends to resolve over time. 5, 6, [12] [13] [14] 16, 17 Sitagliptin and vildagliptin are generally well tolerated, with no characteristic pattern of adverse events associated with the use of these medications. 2, 4, [22] [23] [24] [25] [26] [27] [28] [29] [30] For sitagliptin, adverse events (regardless of causal relationship) reported in at least 5% of patients and more frequently than in the control group included upper respiratory tract infections and nasopharyngitis. [26] [27] [28] [29] [30] For vildagliptin, adverse events reported in at least 5% of patients included upper respiratory tract infections, nasopharyngitis, dizziness, influenza and headache. [22] [23] [24] [25] DPP-4 inhibitors might be a treatment option for patients with a shorter diabetes duration. They do not cause weight gain and have low hypoglycaemic risk -important advantages over sulphonylureas or thiazolidinediones. The effect of exenatide in terms of glycaemic control has been demonstrated in insulin non-inferiority studies. It is the only antidiabetic agent with an additional weight-reduction effect, a desired goal of treatment in any stage of type 2 diabetes, especially in patients in whom weight loss may be desirable. ■
